<rst>
<header>
	<relations>
			<rel name="purpose" type="rst"/>
			<rel name="elaboration" type="rst"/>
			<rel name="concession" type="rst"/>
			<rel name="antithesis" type="rst"/>
			<rel name="condition" type="rst"/>
			<rel name="preparation" type="rst"/>
			<rel name="restatement" type="rst"/>
			<rel name="means" type="rst"/>
			<rel name="attribution" type="rst"/>
			<rel name="joint" type="multinuc"/>
			<rel name="same_unit" type="multinuc"/>
		</relations>
</header>
<body>
<segment id="1" parent="1001" relname="preparation">4.</segment>
<segment id="2" parent="1002" relname="preparation">Materials and Methods</segment>
<segment id="3" parent="1004" relname="span">A search was performed of regulatory and scientific literature</segment>
<segment id="4" parent="1005" relname="span">to identify sources of clinical data</segment>
<segment id="5" parent="4" relname="purpose">to be used</segment>
<segment id="6" parent="1004" relname="purpose">to compare the efficacy and safety of BRAFi/MEKi combination therapies for the treatment of BRAF -mutant metastatic melanoma .</segment>
<segment id="7" parent="1002" relname="joint">The full details of the literature search are outlined in Table S4 .</segment>
<segment id="8" parent="1008" relname="preparation">Four phase III studies were identified :</segment>
<segment id="9" parent="1009" relname="span">coBRIM , a phase III trial of cobimetinib plus vemurafenib versus vemurafenib monotherapy in previously untreated patients with advanced BRAF -mutant melanoma ;</segment>
<segment id="10" parent="1010" relname="joint">COMBI-d , a phase III trial of dabrafenib and trametinib versus dabrafenib monotherapy in previously untreated patients with unresectable stage IIIC or stage IV melanoma with a BRAF V600E or V600K mutation ;</segment>
<segment id="11" parent="1011" relname="joint">COMBI-v , a phase III trial of dabrafenib plus trametinib versus vemurafenib monotherapy in previously untreated patients with unresectable stage IIIC or IV melanoma with BRAF mutation ;</segment>
<segment id="12" parent="1011" relname="joint">and COLUMBUS Part 1 , a phase III trial of encorafenib plus binimetinib versus vemurafenib or encorafenib monotherapy in patients with BRAF -mutant melanoma .</segment>
<segment id="13" parent="1015" relname="span">Three of the identified studies</segment>
<segment id="14" parent="13" relname="elaboration">( coBRIM , COMBI-v , and COLUMBUS Part 1 ) ,</segment>
<segment id="15" parent="1017" relname="span">had vemurafenib 960 mg twice daily</segment>
<segment id="16" parent="15" relname="restatement">( BID )</segment>
<segment id="17" parent="1016" relname="same_unit">as a control arm ,</segment>
<segment id="18" parent="1018" relname="span">and were the chief sources of data for the comparisons</segment>
<segment id="19" parent="18" relname="elaboration">presented here .</segment>
<segment id="20" parent="1022" relname="concession">Although the COMBI-d was identified as part of the initial literature search ,</segment>
<segment id="21" parent="1022" relname="span">it was not included in the efficacy comparison of the cross-trial comparison</segment>
<segment id="22" parent="21" relname="elaboration">due to the lack of a vemurafenib control arm .</segment>
<segment id="23" parent="24" relname="attribution">It should be noted , however ,</segment>
<segment id="24" parent="1024" relname="span">that the outcomes in COMBI-d were substantially similar to those in COMBI-v .</segment>
<segment id="25" parent="1025" relname="span">The key design features of the three included phase III trials are summarized in Table 5 .</segment>
<segment id="26" parent="1026" relname="span">To assist with the completeness of the cross-trial comparison , medical information requests were made to the registered sponsor of cobimetinib , vemurafenib , dabrafenib , trametinib , encorafenib , or binimetinib</segment>
<segment id="27" parent="26" relname="condition">if any missing data were identified .</segment>
<segment id="28" parent="1029" relname="span">The data sources for the coBRIM and COMBI-v trials included primary and secondary publications of data , European public assessment reports</segment>
<segment id="29" parent="28" relname="elaboration">( EPAR ) ,</segment>
<segment id="30" parent="1031" relname="span">U.S. Food and Drug Administration</segment>
<segment id="31" parent="30" relname="restatement">( FDA )</segment>
<segment id="32" parent="1032" relname="span">medical review documents , and the current U.S. prescribing information</segment>
<segment id="33" parent="1033" relname="span">( see Table S5 ,</segment>
<segment id="34" parent="33" relname="elaboration">which illustrates the data sources and cutoff dates for COMBI-v , coBRIM , and COLUMBUS trials ) .</segment>
<segment id="35" parent="1036" relname="span">The data sources for the COLUMBUS trial include a primary publication , U.S. prescribing information , and Array BioPharma data on file .</segment>
<segment id="36" parent="1038" relname="span">The efficacy outcomes</segment>
<segment id="37" parent="1039" relname="span">presented are PFS , objective response rate</segment>
<segment id="38" parent="37" relname="elaboration">( ORR ) ,</segment>
<segment id="39" parent="1041" relname="span">duration of response</segment>
<segment id="40" parent="39" relname="restatement">( DOR )</segment>
<segment id="41" parent="1040" relname="same_unit">per investigator assessment , and OS .</segment>
<segment id="42" parent="1044" relname="span">The assessments of the tumor response across the studies were performed</segment>
<segment id="43" parent="1045" relname="span">using Response Evaluation Criteria in Solid Tumors</segment>
<segment id="44" parent="43" relname="restatement">( RECIST )</segment>
<segment id="45" parent="1043" relname="same_unit">version 1.1 .</segment>
<segment id="46" parent="1046" relname="span">The safety comparisons were made</segment>
<segment id="47" parent="1048" relname="span">using the adverse event</segment>
<segment id="48" parent="47" relname="elaboration">( any untoward medical occurrence regardless of causal relationship )</segment>
<segment id="49" parent="1049" relname="span">and adverse drug reaction</segment>
<segment id="50" parent="1050" relname="same_unit">( noxious and unintended responses with at least a reasonable possibility of a causal relationship )</segment>
<segment id="51" parent="1050" relname="same_unit">data .</segment>
<segment id="52" parent="1053" relname="span">The adverse event data included the overall summaries</segment>
<segment id="53" parent="1054" relname="span">( comprising all-grade , serious , and grade 3/4 AEs , and AEs</segment>
<segment id="54" parent="53" relname="elaboration">leading to death , dose interruption/modification , and discontinuation )</segment>
<segment id="55" parent="1052" relname="same_unit">and the incidence of specific all-grade and grade 3/4 AEs by individual preferred terms per the MedDRA dictionary .</segment>
<segment id="56" parent="1057" relname="span">All studies utilized the National Cancer Institute</segment>
<segment id="57" parent="56" relname="restatement">( NCI )</segment>
<segment id="58" parent="1059" relname="span">Common Terminology Criteria for Adverse Events</segment>
<segment id="59" parent="58" relname="restatement">( CTCAE )</segment>
<segment id="60" parent="1059" relname="purpose">to assess severity .</segment>
<segment id="61" parent="1061" relname="span">The coBRIM and COMBI-v trials used version 4.0 ,</segment>
<segment id="62" parent="61" relname="antithesis">whereas the COLUMBUS trial used version 4.03 .</segment>
<segment id="63" parent="1008" relname="joint">The primary source of data on adverse drug reactions was the available U.S. prescribing information .</segment>
<segment id="64" parent="1064" relname="span">The additional adverse event data for the dabrafenib plus trametinib combination was derived from the COMBI-d trial .</segment>
<segment id="65" parent="64" relname="elaboration">For the cobimetinib plus vemurafenib combination , the coBRIM trial was utilized .</segment>
<segment id="66" parent="1008" relname="joint">The COLUMBUS study was utilized as a source of additional information for adverse events for the encorafenib plus binimetinib combination .</segment>
<group id="1000" type="span" />
<group id="1001" type="span" parent="1000" relname="span"/>
<group id="1002" type="multinuc" parent="1001" relname="span"/>
<group id="1003" type="span" parent="1002" relname="joint"/>
<group id="1004" type="span" parent="1003" relname="span"/>
<group id="1005" type="span" parent="3" relname="purpose"/>
<group id="1007" type="span" parent="1002" relname="joint"/>
<group id="1008" type="multinuc" parent="1007" relname="span"/>
<group id="1009" type="span" parent="1008" relname="joint"/>
<group id="1010" type="multinuc" parent="9" relname="elaboration"/>
<group id="1011" type="multinuc" parent="1010" relname="joint"/>
<group id="1014" type="multinuc" parent="1008" relname="joint"/>
<group id="1015" type="span" parent="1014" relname="same_unit"/>
<group id="1016" type="multinuc" parent="1014" relname="same_unit"/>
<group id="1017" type="span" parent="1016" relname="same_unit"/>
<group id="1018" type="span" parent="1008" relname="joint"/>
<group id="1020" type="span" parent="1008" relname="joint"/>
<group id="1021" type="span" parent="1020" relname="span"/>
<group id="1022" type="span" parent="1021" relname="span"/>
<group id="1023" type="multinuc" parent="1021" relname="elaboration"/>
<group id="1024" type="span" parent="1023" relname="joint"/>
<group id="1025" type="span" parent="1023" relname="joint"/>
<group id="1026" type="span" parent="25" relname="purpose"/>
<group id="1028" type="multinuc" parent="1008" relname="joint"/>
<group id="1029" type="span" parent="1028" relname="same_unit"/>
<group id="1030" type="multinuc" parent="1028" relname="same_unit"/>
<group id="1031" type="span" parent="1030" relname="same_unit"/>
<group id="1032" type="span" parent="1030" relname="same_unit"/>
<group id="1033" type="span" parent="32" relname="elaboration"/>
<group id="1035" type="span" parent="1008" relname="joint"/>
<group id="1036" type="span" parent="1035" relname="span"/>
<group id="1037" type="multinuc" parent="35" relname="elaboration"/>
<group id="1038" type="span" parent="1037" relname="same_unit"/>
<group id="1039" type="span" parent="36" relname="elaboration"/>
<group id="1040" type="multinuc" parent="1037" relname="same_unit"/>
<group id="1041" type="span" parent="1040" relname="same_unit"/>
<group id="1042" type="span" parent="1036" relname="elaboration"/>
<group id="1043" type="multinuc" parent="1042" relname="span"/>
<group id="1044" type="span" parent="1043" relname="same_unit"/>
<group id="1045" type="span" parent="42" relname="means"/>
<group id="1046" type="span" parent="1043" relname="elaboration"/>
<group id="1047" type="multinuc" parent="46" relname="means"/>
<group id="1048" type="span" parent="1047" relname="same_unit"/>
<group id="1049" type="span" parent="1047" relname="same_unit"/>
<group id="1050" type="multinuc" parent="49" relname="elaboration"/>
<group id="1052" type="multinuc" parent="1008" relname="joint"/>
<group id="1053" type="span" parent="1052" relname="same_unit"/>
<group id="1054" type="span" parent="52" relname="elaboration"/>
<group id="1056" type="multinuc" parent="1008" relname="joint"/>
<group id="1057" type="span" parent="1056" relname="same_unit"/>
<group id="1058" type="span" parent="1056" relname="same_unit"/>
<group id="1059" type="span" parent="1058" relname="span"/>
<group id="1061" type="span" parent="1008" relname="joint"/>
<group id="1064" type="span" parent="1008" relname="joint"/>
	</body>
</rst>
